Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents. VCR is an M-phase cell cycle-specific anticancer drug with activity that is concen...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer chemotherapy and pharmacology Vol. 71; no. 3; pp. 555 - 564
Main Authors:	Silverman, Jeffrey A., Deitcher, Steven R.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer-Verlag 01.03.2013 Springer
Subjects:	Animals Antineoplastic agents Antineoplastic Agents, Phytogenic - pharmacokinetics Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Cancer Research Dogs Drug Administration Schedule Drug Carriers Humans Liposomes Maximum Tolerated Dose Medical sciences Medicine Medicine & Public Health Mice Neoplasms - drug therapy Oncology Pharmacology. Drug treatments Pharmacology/Toxicology Phospholipids - chemistry Rats Review Review Article Vincristine - analogs & derivatives Vincristine - pharmacokinetics Vincristine - pharmacology Vincristine - therapeutic use Liposome Marqibo VSLI Xenograft Pharmacokinetics Vincristine Antineoplastic agent Pharmacokinetic pharmacodynamic relationship Drug carrier Transplantation Injection Heterotransplantation Sulfates Alkaloid Treatment Surgery Animal Graft Antimitotic
ISSN:	0344-5704, 1432-0843, 1432-0843
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!